SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR MARKETING OF "LIRAGLUTIDE INJECTION"

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the "Liraglutide Injection" (trade name: Beilelin® (貝樂林®)) developed by the Group has obtained approval for marketing from the National Medical Products Administration of China for the blood sugar control in adult patients with type 2 diabetes.

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) analogue with 97% of homology to human GLP-1. GLP-1 is an endogenous enteric insulinotropic hormone that enhances glucose-dependent insulin secretion from pancreatic β-cells. In addition to pancreatic cells, GLP-1 receptors are widely present in organ tissues including the gastrointestinal, lung, brain, kidney and cardiovascular systems [1]. Liraglutide prolongs the half-life of GLP-1 on the basis of retaining the physiological action characteristics of GLP-1 and achieves a good glucose-lowering effect with once-daily administration. In addition to type 2 diabetes, liraglutide can also provide significant benefits to obese patients in weight control and treatment of cardiovascular disorders and neurological diseases [2].

Currently, liraglutide has been included in various guides such as the American Diabetes Association (ADA) Diabetes Diagnostic and Treatment Criteria (2024 Edition), the Chinese Guidelines for the Prevention and Management of Type 2 Diabetes Mellitus (2020 Edition), and the Expert Consensus on the Clinical Application of Glucose-Lowering Drugs to Type 2 Diabetes Mellitus Adult Patients with Cardiac and Kidney Diseases in China. The market size of diabetes drugs in China exceeded RMB60 billion in 2022 and is expected to break through RMB130 billion by 2030.

The active pharmaceutical ingredients (API) production and preparation process of Beilelin® is lengthy and complex with difficulty in quality control. The Group has effectively enhanced the manageability of the API process, quality and cost by developing its entire process procedure and manufacturing its key enzymes and acylation modifiers. The Group has several sets of upgraded bioreactors with sufficient

production capacity to ensure consistent manufacturing of high-quality pharmaceuticals. Besides liraglutide, the Group is developing semaglutide, which is currently in clinical phase III and is expected to bring benefit to hundreds of millions of Chinese patients with diabetes and obesity.

Sources:

[1] Chinese Diabetes Society. Consensus on the Clinical Application of Glucagon-like Peptide 1 for Glucose-Lowering[J]. Chinese Journal of Diabetes, 2014,6(1): 14-20.

[2] LI Ying, GAO Shan, ZHANG Rong, LI Baiyan. Progress of Clinical Application of Liraglutide and its Mechanism of Action[J]. Modern Drugs and Clinical Study, 2022,37(1): 197-202.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 25 June 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.